First U.S. ANDA submission expands integrated development
Connecting API knowledge with finished-dose development and regulatory filing.
Connecting API knowledge with finished-dose development and regulatory filing.
Revenue of INR 5,753 million and EBITDA of INR 877 million reported for Q1 FY27.
Company reports its fourth consecutive NIL 483 inspection outcome.